



For immediate release 2.00pm: 5 October 2015

HVIVO PLC
("hVIVO" or the "Company")

Directors' Dealings

hVIVO plc (AIM: HVO), the pioneer of human challenge models of disease, announces that application has been made to AIM for the admission of 6,026 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jaime Ellertson (Non-Executive Chairman) and Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of their letters of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Ellertson and Mr Winschel had entered into binding commitments to purchase \$20,000 and £4,000 of hVIVO plc new ordinary shares per quarter respectively. The New Ordinary Shares represent their investments for the quarter ended 30 September 2015. On 5 October 2015, Mr Ellertson invested in an additional 4,616 ordinary shares and Mr Winschel invested in an additional 1,410 ordinary shares.

Following admission of the 6,026 New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 68,941,673 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 9 October 2015. Following Admission, Mr Ellertson and Mr Winschel will be interested in a total of 25,165 and 26,413 ordinary shares of 5.0p in the Company respectively, each representing less than 0.1% of the Company's issued share capital.

For further information please contact:

hVIVO plc

+44 207 756 1300

Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries

+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc (“hVIVO”) is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 40 clinical studies, involving more than 2,000 volunteers for a range of leading industry, governmental and academic clients.